Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Nevro Corp.
Saluda’s Evoke SCS Set To Join Competitive US Spine-Stim Market In Late 2022
The Australian company secured $125m in financing to support commercialization of the Evoke SCS system for chronic pain beginning in late 2022. The US FDA approved Evoke SCS for chronic intractable pain of the trunk and/or limbs, the third major FDA approval of an SCS technology this year so far.
Nevro And Medtronic Announce FDA Approval Of Spinal Cord Stimulation Label Expansions
The FDA approved a diabetic peripheral neuropathy indication for Medtronic’s Intellis and Vanta spinal cord stimulators a few days after expanding the indication for Senza Nevro’s spinal cord stimulation system to include non-surgical refractory back pain.
Minute Insight: Nevro Secures Coverage For HFX Pain Therapy From Largest US Insurance Company
UnitedHealthcare will provide coverage for Nevro’s HFX spinal cord stimulation therapy for the treatment of painful diabetic neuropathy beginning on 1 March. Analysts believe the decision bodes well for the company’s chances of securing coverage from other insurers.
Nevro Turns To Clinical Evidence To Attract Doctors, Patients And Reimbursement For Pain Therapy
The FDA recently approved Nevro’s Senza high-frequency spinal cord stimulation systems to treat pain caused by diabetic neuropathy. Now it plans to expand its proprietary HFX high-frequency treatment to more indications.
Company Information
- Industry
-
Medical Devices
- Implantable Devices
- Other Names / Subsidiaries
-
- Nevro Medical Limited
- Nevro Medical Pty Ltd.
- Nevro Medical Sarl